Constantine Chinoporos - 19 Dec 2025 Form 4 Insider Report for Applied Therapeutics, Inc. (APLT)

Role: Chief Operating Officer and Chief Business Officer
Signature: /s/ Leslie D. Funtleyder, as attorney-in-fact
Issuer symbol: APLT
Transactions as of: 19 Dec 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Feb 2026, 19:03:25 UTC
Previous filing: 26 Mar 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Chinoporos Constantine	Chief Operating Officer and Chief Business Officer	C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK	/s/ Leslie D. Funtleyder, as attorney-in-fact	03 Feb 2026	0002014509

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLT	Common Stock	Award	$0	+437,500	+71%	$0.000000	1,057,111	19 Dec 2025	Direct	F1, F2
transaction	APLT	Common Stock	Disposed to Issuer		-1,000,000	-95%		57,111	03 Feb 2026	Direct	F3, F4
transaction	APLT	Common Stock	Disposition pursuant to a tender of shares in a change of control transaction		-57,111	-100%		0	03 Feb 2026	Direct	F3, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Constantine Chinoporos is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date.
F2	The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the overstatement of the total holdings.
F3	Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").
F4	Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.
F5	Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.

Remarks:

Chief Operating Officer and Chief Business Officer